Sino Biopharmaceutical enters exclusive license agreement with AstraZeneca for development, manufacturing and commercialization of PDE3/4 inhibitor, TQC3721

Sino Biopharmaceutical Limited, a leading innovation and research and development (R&D)-driven pharmaceutical group in China, announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a

To access the full article, please log in or subscribe.